Urinary Incontinence Therapeutics Global Analysis & Forecast to 2025 Urinary Incontinence Therapeutics Market - Global

Urinary Incontinence Therapeutics Market -
Global Industry Analysis, Size, Share, Growth,
Trends, and Forecast 2017 - 2025
Urinary incontinence, an involuntary leakage of urine, is a very common problem
especially among people over 50 years of age. As per the American Academy of
Family Physicians (AAFP), over 26 million Americans experience urinary
incontinence at some point in their lives. This condition depends on the
incontinence type and severity, along with its causative reason. Weakened bladder,
damaged pelvic muscles, and cancer are some of the causes of urinary
incontinence. This problem if not treated, affects the social, economic, and
emotional life of persons affected by it, as chronic urinary incontinence can have a
serious impact on overall health. The urinary incontinence condition is diagnosed
using urodynamic testing or pelvic ultrasound. If diagnosed, the treatment for
urinary incontinence involves a combination of various exercises along with
medications.
Report Detail @
http://www.transparencymarketresearch.com/urinary-incontinence-therapeutics-
market.html
The global urinary incontinence therapeutics market is expected to be driven by
rising demand for treatment of urinary disorders, along with combinational
therapies with improved pharmacokinetic and pharmacodynamic properties.
Furthermore, rise in geriatric population, awareness initiatives along with invention
of effective therapeutics from years of research and development by manufacturers,
is expected to steer the growth of the global urinary incontinence therapeutics
market. However, difficulty in disease diagnosis, along with negligence about
urinary incontinence disorders is anticipated to restrain the market.
The global urinary incontinence therapeutics market has been classified on the
basis of urinary incontinence type, therapeutic class, and distribution channels.
Based on the type of urinary incontinence, the market has been categorized into
stress urinary incontinence, urge urinary incontinence, functional urinary
incontinence, overflow urinary incontinence, and mixed urinary incontinence.
Among these segments, stress urinary incontinence affects more than 30 million
Americans, and its prevalence is higher in women. Based on therapeutic class, the
market has been divided into anticholinergic/antispasmodic agents, skeletal muscle
relaxants, antidepressants, alpha blockers, and others. The others segment